Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IV, Multicenter, Randomized, Dose Frequency Study of the Safety and Efficacy of Cerezyme® Infusions Every Four Weeks Versus Every Two Weeks in the Maintenance Therapy of Patients With Type 1 Gaucher Disease

NCT00364858 is registered in ClinicalTrials.gov with Genzyme, a Sanofi Company as lead sponsor.

NCT NCT00364858
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00364858 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IV, Multicenter, Randomized, Dose Frequency Study of the Safety and Efficacy of Cerezyme® Infusions Every Four Weeks Versus Every Two Weeks in the Maintenance Therapy of Patients With Type 1 Gaucher Disease
Lead sponsor
Genzyme, a Sanofi Company
Phase
Phase 4
Overall status
Completed
Start date
December 31, 2001
Completion date
February 28, 2007
Enrollment
95 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

cerebroside lipidosis syndrome, gaucher disease, non-neuronopathic form, gaucher disease, type 1, glucocerebrosidase deficiency disease, glucosylceramide beta-glucosidase deficiency disease